Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Volume Increase - What's Next?

Key Points

• Bayer Aktiengesellschaft's trading volume surged by 114% to 1,712,818 shares on Monday, with the stock currently priced at $7.88.
• Recent analyst ratings show a mixed outlook with two strong buy, one buy, and two hold ratings, contributing to an average rating of Buy.
• Bayer reported $0.65 EPS for the last quarter, surpassing estimates, with revenues hitting $15.27 billion against a forecast of $13.39 billion.

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) saw an uptick in trading volume on Monday . 1,712,818 shares were traded during trading, an increase of 114% from the previous session's volume of 801,543 shares.The stock last traded at $7.88 and had previously closed at $8.09.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BAYRY. Kepler Capital Markets raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. The Goldman Sachs Group upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Wall Street Zen downgraded Bayer Aktiengesellschaft from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. Finally, Hsbc Global Res upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy".

Bayer Aktiengesellschaft Trading Down 9.2%

The company has a 50 day moving average of $7.81 and a two-hundred day moving average of $6.70. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.79 and a current ratio of 1.25. The stock has a market cap of $28.41 billion, a PE ratio of -7.86 and a beta of 0.91.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.02. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. The business had revenue of $15.27 billion for the quarter, compared to analysts' expectations of $13.39 billion. Sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.